These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 10472443)

  • 1. [Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda].
    Legros D; Fournier C; Gastellu Etchegorry M; Maiso F; Szumilin E
    Bull Soc Pathol Exot; 1999 Jul; 92(3):171-2. PubMed ID: 10472443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).
    Schmid C; Richer M; Bilenge CM; Josenando T; Chappuis F; Manthelot CR; Nangouma A; Doua F; Asumu PN; Simarro PP; Burri C
    J Infect Dis; 2005 Jun; 191(11):1922-31. PubMed ID: 15871127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
    Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
    Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.
    Legros D; Evans S; Maiso F; Enyaru JC; Mbulamberi D
    Trans R Soc Trop Med Hyg; 1999; 93(4):439-42. PubMed ID: 10674099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis.
    Rodgers J; Bradley B; Kennedy PG
    Parasitol Int; 2007 Dec; 56(4):321-4. PubMed ID: 17643344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis.
    Lejon V; Roger I; Mumba Ngoyi D; Menten J; Robays J; N'siesi FX; Bisser S; Boelaert M; Büscher P
    Clin Infect Dis; 2008 Jul; 47(1):15-22. PubMed ID: 18494605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled trial of treatments for second-stage sleeping sickness.
    Woodrow CJ; Abel PM; Krishna S
    J Infect Dis; 2007 Aug; 196(4):650-1. PubMed ID: 17624857
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
    Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
    Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children.
    Eperon G; Schmid C; Loutan L; Chappuis F
    Acta Trop; 2007 Jan; 101(1):31-9. PubMed ID: 17207760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human African trypanosomiasis in Ivory Coast: biological characteristics after treatment. 812 cases treated in the Daloa focus (Ivory Coast)].
    Miezan TW; Dje NN; Doua F; Boa F
    Bull Soc Pathol Exot; 2002 Dec; 95(5):362-5. PubMed ID: 12696377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Melarsoprol].
    Simon F
    Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741
    [No Abstract]   [Full Text] [Related]  

  • 14. Control of human African trypanosomiasis in the Quiçama focus, Angola.
    Ruiz JA; Simarro PP; Josenando T
    Bull World Health Organ; 2002; 80(9):738-45. PubMed ID: 12378293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep structure: a new diagnostic tool for stage determination in sleeping sickness.
    Buguet A; Bisser S; Josenando T; Chapotot F; Cespuglio R
    Acta Trop; 2005 Jan; 93(1):107-17. PubMed ID: 15589803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Human African trypanosomiasis, contributions of experimental models].
    Bouteille B; Millet P; Enanga B; Mezui Me J; Keita M; Jauberteau MO; Georges A; Dumas M
    Bull Soc Pathol Exot; 1998; 91(2):127-32. PubMed ID: 9642464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
    Nok AJ
    Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.
    Chappuis F
    Clin Infect Dis; 2007 Dec; 45(11):1443-5. PubMed ID: 17990226
    [No Abstract]   [Full Text] [Related]  

  • 19. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
    Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arsenical resistance and difluoromethylornithine in the treatment of human African trypanosomiasis].
    Kazyumba GL; Ruppol JF; Tshefu AK; Nkanga N
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):591-4. PubMed ID: 3143492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.